91 related articles for article (PubMed ID: 26826502)
1. Losartan and captopril treatment rescue normal thrombus formation in microfibril associated glycoprotein-1 (MAGP1) deficient mice.
Vassequi-Silva T; Pereira DS; Nery Diez ACC; Braga GG; Godoy JA; Mendes CB; Dos Santos L; Krieger JE; Antunes E; Costa FTM; Vicente CP; Werneck CC
Thromb Res; 2016 Feb; 138():7-15. PubMed ID: 26826502
[TBL] [Abstract][Full Text] [Related]
2. Mice lacking the extracellular matrix protein MAGP1 display delayed thrombotic occlusion following vessel injury.
Werneck CC; Vicente CP; Weinberg JS; Shifren A; Pierce RA; Broekelmann TJ; Tollefsen DM; Mecham RP
Blood; 2008 Apr; 111(8):4137-44. PubMed ID: 18281502
[TBL] [Abstract][Full Text] [Related]
3. The antithrombotic effect of captopril and losartan on experimental arterial thrombosis in rats.
Chabielska E; Pawlak R; Golatowski J; Buczko W
J Physiol Pharmacol; 1998 Jun; 49(2):251-60. PubMed ID: 9670108
[TBL] [Abstract][Full Text] [Related]
4. The extracellular matrix protein MAGP1 supports thermogenesis and protects against obesity and diabetes through regulation of TGF-β.
Craft CS; Pietka TA; Schappe T; Coleman T; Combs MD; Klein S; Abumrad NA; Mecham RP
Diabetes; 2014 Jun; 63(6):1920-32. PubMed ID: 24458361
[TBL] [Abstract][Full Text] [Related]
5. Microfibril-associated glycoprotein 2 (MAGP2) loss of function has pleiotropic effects in vivo.
Combs MD; Knutsen RH; Broekelmann TJ; Toennies HM; Brett TJ; Miller CA; Kober DL; Craft CS; Atkinson JJ; Shipley JM; Trask BC; Mecham RP
J Biol Chem; 2013 Oct; 288(40):28869-80. PubMed ID: 23963447
[TBL] [Abstract][Full Text] [Related]
6. Oophorectomy-induced bone loss is attenuated in MAGP1-deficient mice.
Craft CS; Broekelmann TJ; Zou W; Chappel JC; Teitelbaum SL; Mecham RP
J Cell Biochem; 2012 Jan; 113(1):93-9. PubMed ID: 21898536
[TBL] [Abstract][Full Text] [Related]
7. Functional analysis of zebrafish microfibril-associated glycoprotein-1 (Magp1) in vivo reveals roles for microfibrils in vascular development and function.
Chen E; Larson JD; Ekker SC
Blood; 2006 Jun; 107(11):4364-74. PubMed ID: 16469878
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of arterial thrombogenesis by quinapril but not losartan.
Bavry AA; Li D; Zander DS; Phillips MI; Mehta JL
J Cardiovasc Pharmacol Ther; 2000 Apr; 5(2):121-7. PubMed ID: 11150391
[TBL] [Abstract][Full Text] [Related]
9. Characterization of metabolic health in mouse models of fibrillin-1 perturbation.
Walji TA; Turecamo SE; DeMarsilis AJ; Sakai LY; Mecham RP; Craft CS
Matrix Biol; 2016 Sep; 55():63-76. PubMed ID: 26902431
[TBL] [Abstract][Full Text] [Related]
10. Prevention of occlusive arterial thrombus formation by a single loading dose of prasugrel suppresses neointimal hyperplasia in mice.
Ohno K; Tomizawa A; Jakubowski JA; Mizuno M; Sugidachi A
Thromb Res; 2015 Dec; 136(6):1245-51. PubMed ID: 26489728
[TBL] [Abstract][Full Text] [Related]
11. Microfibril-associated glycoprotein-1, an extracellular matrix regulator of bone remodeling.
Craft CS; Zou W; Watkins M; Grimston S; Brodt MD; Broekelmann TJ; Weinbaum JS; Teitelbaum SL; Pierce RA; Civitelli R; Silva MJ; Mecham RP
J Biol Chem; 2010 Jul; 285(31):23858-67. PubMed ID: 20501659
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the in vivo antiplatelet activity of the antihypertensive agent losartan.
Murad JP; Espinosa EV; Ting HJ; Khasawneh FT
J Cardiovasc Pharmacol Ther; 2012 Sep; 17(3):308-14. PubMed ID: 22123197
[TBL] [Abstract][Full Text] [Related]
13. Antithrombotic effect of tissue and plasma type angiotensin converting enzyme inhibitors in experimental thrombosis in rats.
Wojewódzka-Zelezniakowicz M; Chabielska E; Mogielnicki A; Kramkowski K; Karp A; Opadczuk A; Domaniewski T; Malinowska-Zaprzałka M; Buczko W
J Physiol Pharmacol; 2006 Jun; 57(2):231-45. PubMed ID: 16845228
[TBL] [Abstract][Full Text] [Related]
14. Adamtsl2 deletion results in bronchial fibrillin microfibril accumulation and bronchial epithelial dysplasia--a novel mouse model providing insights into geleophysic dysplasia.
Hubmacher D; Wang LW; Mecham RP; Reinhardt DP; Apte SS
Dis Model Mech; 2015 May; 8(5):487-99. PubMed ID: 25762570
[TBL] [Abstract][Full Text] [Related]
15. Atorvastatin, Losartan and Captopril Lead to Upregulation of TGF-β, and Downregulation of IL-6 in Coronary Artery Disease and Hypertension.
Sepehri Z; Masoumi M; Ebrahimi N; Kiani Z; Nasiri AA; Kohan F; Sheikh Fathollahi M; Kazemi Arababadi M; Asadikaram G
PLoS One; 2016; 11(12):e0168312. PubMed ID: 28033321
[TBL] [Abstract][Full Text] [Related]
16. The intracellular form of human MAGP1 elicits a complex and specific transcriptional response.
Segade F; Suganuma N; Mychaleckyj JC; Mecham RP
Int J Biochem Cell Biol; 2007; 39(12):2303-13. PubMed ID: 17692555
[TBL] [Abstract][Full Text] [Related]
17. Temporary losartan or captopril in young SHR induces malignant hypertension despite initial normotension.
Racasan S; Hahnel B; van der Giezen DM; Blezer EL; Goldschmeding R; Braam B; Kriz W; Koomans HA; Joles JA
Kidney Int; 2004 Feb; 65(2):575-81. PubMed ID: 14717927
[TBL] [Abstract][Full Text] [Related]
18. Effects of drugs affecting the renin-angiotensin system on venous thrombosis in normotensive rats.
Chabielska E; Pawlak R; Buczko W
Pol J Pharmacol; 1996; 48(1):89-91. PubMed ID: 9112634
[TBL] [Abstract][Full Text] [Related]
19. Losartan metabolite EXP3174 reduces the weight of formed thrombus in 2K1C hypertensive rats.
Gromotowicz-Poplawska A; Nazarko-Sadowska J; Chabielska E
J Physiol Pharmacol; 2019 Jun; 70(3):. PubMed ID: 31566190
[TBL] [Abstract][Full Text] [Related]
20. Modification of cardiac subcellular remodeling due to pressure overload by captopril and losartan.
Liu X; Sentex E; Golfman L; Takeda S; Osada M; Dhalla NS
Clin Exp Hypertens; 1999; 21(1-2):145-56. PubMed ID: 10052650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
